- EMVision Medical Devices (EMV) has entered a trading halt ahead of a capital raise announcement
- Prior to entering a trading halt, EMVision delivered encouraging haemorrhagic images from its clinical trial in haemorrhagic stroke patients
- Pleasingly, a selection of the imaging algorithms could detect, localise and classify haemorrhagic stroke
- EMVision is aiming to commercialise a bedside and prehospital device to assist clinicians with earlier interventions and treatments for stroke patients
- The company also outlined $5.41 million in cash reserves at the end of the June quarter
- Company shares last traded for $1.69 on July 21
EMVision Medical Devices (EMV) has entered a trading halt ahead of a capital raise announcement.
The trading halt will remain in place until the commencement of normal trading on Friday, July 24, unless the announcement is released earlier.
This morning, prior to entering a trading halt, EMVision delivered encouraging haemorrhagic images from its clinical trial.
In the small group of patients, who were selected based on their haemorrhagic stroke type, a selection of the company’s imaging algorithms was able to detect, localise and classify haemorrhagic stroke.
The valuable data has demonstrated the potential of EMVision’s techniques to not only detect and localise strokes, but importantly to classify them based on differences between blood, ischaemic tissue or oedema.
Whilst haemorrhagic strokes represent around just 13 per cent of all stroke cases, early exclusion is crucial in providing timely thrombolytic therapy and ideally would be possible before arriving at the hospital.
“These preliminary images support the approach we are taking to deliver a unique bedside device for stroke monitoring, and in the future, prehospital, to assist clinicians with earlier interventions and treatment choices,” Managing Director and CEO Dr Ron Weinberger said.
The clinical trial will provide the relevant information needed to commercialise EMVision’s portable medical imaging product and progress regulatory approvals.
EMVision expects to complete its 30-patient enrolment process by the end of this quarter. Once this is finalised, all data and final results will undergo a detailed review.
The company also outlined $5.41 million in cash reserves at the end of the June quarter. As of June 30, the medical device specialist received roughly $2.11 million from the government and $413,000 from grant partners.
Company shares last traded for $1.69 on July 21.